Syneos Health - Collaborating to Address the Challenge of COVID-19

We are here to listen, collaborate and be agile as we navigate this global health crisis together. During this time, we continue to look ahead and evolve our ways of working, ensuring that our processes, people and innovative technologies enable the continued development and delivery of medicines to patients worldwide.

 

Explore this page to learn more about our preparedness, resources and perspectives on COVID-19.
 

 

Corporate Updates Corporate Updates

During this challenging time we are committed to frequent, clear communication about the steps we are taking in response to the COVID-19 crisis, with the goal of ensuring that the vital work of delivering new therapies to patients continues.

 

 

Supporting Monitoring Continuity  Supporting Monitoring Continuity

Keeping clinical trials running during a pandemic requires utilization of all the remote monitoring tools and technologies at our disposal to maintain data quality, support clinical sites and keep patients safe. 

 

 

Infectious Disease Expertise  Infectious Disease Expertise

Clinical trials to test vaccines and treatments during a pandemic demand extreme speed in start-up, a rapid operational tempo and access to subjects in high-risk areas for the targeted disease.

 

 

 Virtual Field Teams 

Now more than ever, infrastructure and flexible processes are needed for deploying virtual teams and ensure business continuity through remote engagement.

 

 

Multimedia Content  COVID-19 Multimedia

 

The Syneos Health Podcast

Our Coronavirus Special Edition Podcast Series explores, from an operational standpoint, the impact of COVID-19 on the biopharmaceutical industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues.

 

For more perspectives on helpful strategies at this time –
from virtual trials to crisis communications:

Visit Our Insights Hub

 


 

COVID-19 Special Initiative:

Ventilator Initiative Task Force  Ventilator Initiative Task Force

 

A critical shortage of mechanical ventilators is anticipated in many countries, including the United States, because of the COVID-19 pandemic. Recent FDA guidance provides for the use existing hospital BiPAP (bi-level positive airway pressure) machines on an emergency basis to spare mechanical ventilation if necessary. Syneos Health has launched the Ventilator Initiative Task Force as a platform for mobilizing awareness and action, and to support healthcare professionals with education, training and research.